Please provide your email address to receive an email when new articles are posted on . The novel gene therapy is aimed at optogenetic vision restoration in diseases causing blindness. The Series A ...

Ray Therapeutics (RayTx), an industry-leading clinical-stage biopharmaceutical company pioneering differentiated vision ...

DALLAS, March 30, 2026 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with ...

This study presents a novel implantable retina that uses multilayer optical filters to convert near-infrared light into ...

Married couple Jean Bennett and Albert Maguire developed Luxturna, which helped a patient see their child’s face for the first time ...

Gene therapy emerges as a transformative force in ophthalmology, offering renewed hope for patients with retinal diseases. This innovative approach targets both inherited and acquired conditions, ...

Researchers have developed an implantable artificial retina that converts near-infrared light into electrical signals, ...

Please provide your email address to receive an email when new articles are posted on . The trial, which included 27 participants, met its safety and efficacy endpoints at 52 weeks and 76 weeks. The ...

BIO Capital continues support as founding investor, having backed Ray Therapeutics since seed funding in 2021 through Series ...

The Breakthrough Prize Foundation awarded researchers involved in developing gene therapies for blindness and sickle cell ...